Azelaic Acid 15%

There is a particular kind of frustration that comes with finding a skincare product that genuinely works for you, only to have it yanked away. For the patients who relied on Apostrophe's Azelaic Acid 15% cream, March 2025 delivered exactly that gut punch when Hims & Hers — the parent company that had acquired Apostrophe for a cool $190 million in 2021 — decided to shutter the entire platform to focus on its booming weight loss business. The prescription skincare equivalent of your favorite restaurant closing to become a juice bar.

But before the obituary, the formula itself deserves its due. Apostrophe's Azelaic Acid 15% was a compounded prescription cream that combined two dermatological heavyweights: azelaic acid at full prescription strength and niacinamide at a clinically relevant 4%. The pairing was smart. Azelaic acid does the heavy lifting — killing acne-causing bacteria, normalizing the rate at which skin cells shed inside pores, and inhibiting tyrosinase to fade dark spots. Niacinamide reinforces from the flanks, calming inflammation, reducing sebum production, and strengthening the moisture barrier so the azelaic acid can do its work without leaving the skin compromised.

The vehicle was deliberately minimal. Aloe vera juice as the primary soothing agent, caprylic/capric triglycerides for a touch of emollience, tocopheryl acetate for antioxidant backup, and phenoxyethanol as the sole preservative. No fragrance, no unnecessary botanical extracts, no Instagram-friendly but dermatologically questionable additions. This was a formula designed by dermatologists who wanted their patients to use it consistently without their skin throwing a fit.

Application was straightforward. The white cream dispensed from an airless pump — a thoughtful packaging choice that prevented contamination and ensured consistent dosing. It spread easily without dragging and absorbed within about a minute, leaving behind a matte, barely-there finish that layered well under moisturizer and sunscreen. The initial tingling that most azelaic acid users experience was present but manageable, typically subsiding within the first two weeks of use.

Where this product truly earned its following was in the combination of conditions it could address simultaneously. A patient dealing with hormonal acne along the jawline and lingering dark spots from previous breakouts could treat both with a single product, applied once or twice daily. Someone with mild rosacea and occasional breakouts found that the dual anti-inflammatory action of azelaic acid and niacinamide calmed both concerns without the irritation that retinoids or benzoyl peroxide might trigger. And critically, this was one of the few prescription-strength options safe for use during pregnancy — a gap that few other actives could fill.

The clinical evidence supporting 15% azelaic acid is robust and spans decades. Studies have demonstrated comparable efficacy to adapalene 0.1% for acne with significantly less irritation, meaningful improvements in papulopustular rosacea rivaling metronidazole, and measurable lightening of post-inflammatory hyperpigmentation. The addition of niacinamide at 4% was not merely trendy; multiple controlled trials have shown niacinamide's ability to reduce sebum excretion, improve skin barrier function, and provide its own independent brightening effect through inhibition of melanosome transfer.

The limitations were real, however. Azelaic acid at any concentration is not a fast worker. Users expecting the rapid visible peeling of a retinoid or the overnight bacterial knockout of benzoyl peroxide found azelaic acid's gradual, steady approach frustrating. Eight to twelve weeks for meaningful acne improvement, potentially sixteen or more for significant pigmentation fading — that is a long time to wait, especially when you are paying a subscription premium for the privilege.

And the cost was the elephant in the room. Apostrophe's teledermatology model — consultation fee plus ongoing prescription costs — placed this compounded cream at a significant markup over what a patient might pay for generic azelaic acid gel through traditional channels with insurance. The convenience of skipping the dermatologist's office was genuine, but convenience has always been an expensive luxury in healthcare.

The texture and user experience, while pleasant, were nothing remarkable. This was a workmanlike cream that did its job without fanfare. It did not have the elegant sensory profile of a Korean beauty serum or the satisfying slip of a high-end treatment. It was clinical in the best and most literal sense — effective, unembellished, and focused entirely on outcomes.

For the patients who found their rhythm with this product — who had navigated the initial tingling, waited through the slow weeks, and finally arrived at clearer, more even-toned skin — the brand's closure was a genuine loss. The good news is that azelaic acid at 15% is available through other channels, and the niacinamide can easily be added as a separate step. The formula was excellent, but the ingredients are not proprietary. What Apostrophe provided was the combination and the convenience, and while both are replaceable, the sudden disappearance reminded patients that in DTC healthcare, your prescription is only as stable as the parent company's quarterly earnings call.

Formula

The Science

Azelaic acid at 15% concentration is among the most versatile prescription actives in dermatology, supported by decades of clinical evidence. A 2023 systematic review by King et al. published in the Journal of Cosmetic Dermatology evaluated azelaic acid's efficacy across acne, rosacea, melasma, and skin aging, concluding that 15-20% concentrations produced clinically meaningful improvements across all four indications with a favorable safety profile.

For acne specifically, azelaic acid works through a triple mechanism: antimicrobial activity against Cutibacterium acnes, normalization of follicular keratinization (preventing the clogged pores that initiate breakouts), and anti-inflammatory effects that reduce the redness and swelling of active lesions. A comparative study demonstrated that azelaic acid 15% gel achieved acne lesion reduction comparable to adapalene 0.1% gel over nine months, with significantly lower irritation scores — a meaningful advantage for patients who cannot tolerate retinoids.

The combination with niacinamide at 4% in this formulation is pharmacologically rational. Niacinamide independently reduces sebum production by modulating lipid synthesis in sebocytes, strengthens the skin barrier through increased ceramide production, and inhibits melanosome transfer from melanocytes to keratinocytes — providing a complementary brightening mechanism to azelaic acid's direct tyrosinase inhibition. While no published trial has evaluated this specific Apostrophe formulation, the individual actives at these concentrations each have robust evidence supporting their efficacy.

For rosacea, multiple randomized controlled trials have established 15% azelaic acid as a first-line treatment for papulopustular subtype, with efficacy comparable to or exceeding metronidazole 0.75% gel. A 2024 study published in the Journal of Dermatological Treatment confirmed that azelaic acid 15% significantly reduced post-acne hyperpigmentation indices and melanin content compared to vehicle control, reinforcing the ingredient's dual utility for both active lesions and their aftermath.

References

1. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging — Journal of Cosmetic Dermatology (2023)
2. Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Hyperpigmentation — Journal of Dermatological Treatment (2024)
3. Azelaic acid 15% gel in the treatment of rosacea — Expert Opinion on Pharmacotherapy (2008)

Dermatologist Perspective

Dermatologists have long valued azelaic acid as a versatile and well-tolerated treatment option, particularly for patients who cannot use retinoids due to pregnancy, breastfeeding, or sensitivity concerns. Board-certified dermatologists frequently note that 15% azelaic acid occupies a unique therapeutic niche — it addresses acne, rosacea, and hyperpigmentation simultaneously, which few other single actives can claim. The combination with niacinamide at 4% in this formulation aligns with evidence-based dermatological practice, as both ingredients have complementary mechanisms of action. Dermatologists commonly advise starting with once-daily evening application and titrating to twice daily as tolerance builds. The pregnancy safety profile makes this category of product especially valuable in clinical practice, where the overlap between hormonal acne and family planning is common.

Guidance

Apostrophe built its reputation on making prescription-strength actives accessible through teledermatology, bypassing traditional dermatologist wait times. This azelaic acid formula became popular among patients seeking a pregnancy-safe alternative to retinoids for acne and pigmentation. The brand was acquired by Hims & Hers in 2021 for $190 million, but was abruptly shut down in March 2025 as the parent company shifted focus to weight loss offerings.

About Apostrophe Emerging Brand (2–5 years)

Apostrophe launched in 2019 as a rebrand of YoDerm (founded 2012), a teledermatology platform connecting patients with board-certified dermatologists who prescribed customized compounded formulations. The brand was acquired by Hims & Hers for $190 million in 2021 and was shut down in March 2025.

Brand founded: 2012 · Product launched: 2019

Myth vs. Reality

Myth

Azelaic acid is too weak to treat real acne — you need benzoyl peroxide or retinoids.

Reality

Clinical trials show 15% azelaic acid achieves comparable acne reduction to adapalene 0.1% with significantly less irritation. It works through multiple mechanisms including antimicrobial activity and keratolysis.

Myth

Prescription azelaic acid from teledermatology platforms is the same as pharmacy-compounded generics.

Reality

Apostrophe's formulation was specifically compounded with niacinamide 4% and aloe vera as a vehicle, which differs from generic azelaic acid gels like Finacea that use different inactive ingredients and lack the niacinamide boost.

FAQ

Common Praise

"Effective for stubborn acne and post-acne marks"

"Gentle enough for sensitive skin"

"Noticeable texture improvement within weeks"

"Pregnancy-safe prescription option"

Common Complaints

"Tingling and warmth on initial application"

"Subscription pricing felt expensive"

"Slower results compared to tretinoin for acne"

"Brand was abruptly discontinued"

Notable Endorsements

Board-certified dermatologists prescribed through Apostrophe platformRecommended for pregnancy-safe acne treatment

Appears In

best treatment for acne best treatment for hyperpigmentation best treatment for rosacea best pregnancy safe acne treatment

Related Conditions

acne rosacea hyperpigmentation dark spots texture dullness

Related Ingredients

azelaic acid niacinamide aloe vera vitamin e